PKM and chronic myelogenous leukemia, BCR-ABL1 positive: Targeting PKM2 and STAT5 presents a potential drug target for eradicating IM-resistant CML, as supported by our findings of Chi and IM combination downregulating STAT5 via PKM2 (Fig. 9).